Figure 2.

Inactivation of YAP sensitises the OVCAR‐8 ovarian cancer cells to AZD1775–gemcitabine combination therapy. (A) (i) YAP was depleted using siRNA, and the cells were treated with the indicated concentrations of AZD1775 and gemcitabine for 4 days. Viability was measured using MTT assay. The viability was measured using the absorbance without AZD1775 as 100% in each sample. The data are representative of at least three independent experiments. Significant differences between the groups were evaluated using an independent‐sample t‐test. *P < 0.05. (ii) Colony formation assay. Cells were treated with siRNA, and next day, cells were treated with indicated concentration of AZD1775 with or without 1.5 nm gemcitabine (gem). Data are representative of at least three independent experiments. (B) The cells were treated with indicated concentrations of AZD1775 and gemcitabine for 4 days. The data are representative of at least two independent experiments. cPARP, cleaved PARP. The band intensity was quantified by imagej, and the percentage of cPARP was calculated as cPARP/(full‐length PARP + cPARP) × 100. (C) Robust cell death was induced by AZD1775–gemcitabine in the YAP‐depleted cells. The cells were treated with indicated concentration of AZD1775 and 1.5 nm gemcitabine for 4 days and analysed using flow cytometry. The data are representative of at least three independent experiments. Cells undergoing early and late apoptosis were shown in red and purple rectangles, respectively.